<DOC>
	<DOC>NCT01186991</DOC>
	<brief_summary>This is a randomized, Phase II, double-blind, multicenter, placebo-controlled trial designed to preliminarily estimate the efficacy and evaluate the safety and tolerability of onartuzumab (MetMAb) + bevacizumab + paclitaxel and onartuzumab + placebo + paclitaxel versus placebo + bevacizumab + paclitaxel in participants with metastatic or locally recurrent, triple-negative breast cancer who either have not received treatment (first-line) or have progressed after one conventional cytotoxic chemotherapy regimen (second-line).</brief_summary>
	<brief_title>Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 Histologically confirmed estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2 (HER2)negative (triplenegative) adenocarcinoma of the breast Confirmed availability of tumor tissue Prior therapy with two or more regimens for metastatic breast cancer Any systemic anticancer therapy within 3 weeks prior to Day 1 of Cycle 1 Major surgical procedure, open biopsy, or significant traumatic injury within 30 days prior to Day 1 of Cycle 1 Prior therapy with a taxane for metastatic breast cancer Prior therapy with bevacizumab, sorafenib, sunitinib, or other putative vascular endothelial growth factor (VEGF) pathwaytargeted therapy following diagnosis of breast cancer Prior therapy with hormones and/or trastuzumab Inadequate hematology, renal, or hepatic organ function Bevacizumab Uncontrolled hypertension (systolic pressure greater than [&gt;] 150 millimeters of mercury [mmHg] and/or diastolic pressure &gt; 100 mmHg), with or without antihypertensive medication Evidence of bleeding diathesis or coagulopathy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>